PHAXIAM Therapeutics S.A. company info

What does PHAXIAM Therapeutics S.A. do?
PHAXIAM Therapeutics (EPA:PHXM), (NASDAQ:PHXM) pioneers cutting-edge solutions in pharmaceuticals, focused on transforming lives through innovative therapies. Specializing in precision medicine, PHAXIAM harnesses the power of advanced technologies and deep scientific expertise to develop targeted treatments for challenging diseases. With a commitment to patient-centric care, the company strives for breakthroughs in areas such as oncology, immunology, and rare genetic disorders. PHAXIAM's robust pipeline is propelled by a culture of collaboration, drawing on interdisciplinary insights to drive impactful advancements in healthcare. Positioned at the forefront of therapeutic innovation, PHAXIAM Therapeutics is dedicated to shaping a healthier future for global communities.
PHAXIAM Therapeutics S.A. company media
Company Snapshot

Is PHAXIAM Therapeutics S.A. a public or private company?

key
Ownership
Public

How many people does PHAXIAM Therapeutics S.A. employ?

people
Employees
92

What sector is PHAXIAM Therapeutics S.A. in?

pie chart
Sector
Health Care

Where is the head office for PHAXIAM Therapeutics S.A.?

location pin
Head Office
Lyon, France

What year was PHAXIAM Therapeutics S.A. founded?

founded flag
Year Founded
2004
What does PHAXIAM Therapeutics S.A. specialise in?
/Pharmaceutical Development /Therapeutic Solutions /Drug Discovery /Clinical Trials /Medical Research /Patient Care

What are the products and/or services of PHAXIAM Therapeutics S.A.?

Overview of PHAXIAM Therapeutics S.A. offerings
Precision Oncology Therapies: PHAXIAM Therapeutics specializes in developing precision oncology therapies tailored to individual patient profiles, aiming to revolutionize cancer treatment and improve patient outcomes.
Immunomodulatory Drugs: PHAXIAM's immunomodulatory drugs target the immune system, offering novel approaches to treating autoimmune diseases, inflammatory disorders, and other conditions where immune responses play a central role.
Rare Disease Treatments: PHAXIAM is dedicated to addressing the unmet needs of patients with rare genetic disorders by developing innovative therapies that target the underlying molecular mechanisms of these conditions.
Personalized Medicine Platforms: PHAXIAM leverages advanced personalized medicine platforms to identify biomarkers, predict treatment responses, and tailor therapies to individual patients, optimizing efficacy and minimizing side effects.
Therapeutic Antibodies: The company's portfolio includes therapeutic antibodies designed to selectively target disease-associated antigens, offering precise and potent treatment options across a range of therapeutic areas.
Clinical Research Services: PHAXIAM provides comprehensive clinical research services, including study design, patient recruitment, data analysis, and regulatory support, to advance the development of novel therapeutics from early-stage research through to market approval.

Who is in the executive team of PHAXIAM Therapeutics S.A.?

PHAXIAM Therapeutics S.A. leadership team
  • Mr. Eric  Soyer Ph.D.
    Mr. Eric Soyer Ph.D.
    Deputy CEO, Deputy GM, CFO & COO
  • Dr. Jérôme  Bailly Pharm.D.
    Dr. Jérôme Bailly Pharm.D.
    Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person
  • Mr. Thibaut du Fayet
    Mr. Thibaut du Fayet
    Chief Executive Officer
  • Ms. Céline  Breda
    Ms. Céline Breda
    Chief Technology Officer
  • Ms. Cindy  Fevre
    Ms. Cindy Fevre
    Chief Scientific Officer
  • Naomi  Eichenbaum
    Naomi Eichenbaum
    Director Investor Relations
  • Ms. Anne-Cécile  Fumey
    Ms. Anne-Cécile Fumey
    Vice President of Human Resources
  • Ms. Karine  Charton Ph.D.
    Ms. Karine Charton Ph.D.
    Chief Business Officer